A formulation is disclosed for use in wound healing. The formulation may include hypochlorous acid, a silicone polymer or blend thereof, sodium phosphate, hydrochloric acid, and sodium magnesium silicate. Methods of using and making the wound healing formulation are also disclosed.

The present invention provides for a composition, including: a sufficient first amount of a first active agent dispersion; where the first active agent dispersion has a pKa of 0.1-2.0, where the first active agent dispersion is selected from the group consisting of: an acid cation exchange resin, an acidic zeolite, an acidic clay, an organic acid, an inorganic acid, and any combination thereof, and where the first active agent dispersion includes a plurality of particles; where the plurality of particles has a median diameter of between 0.5-1000 micrometers; and a sufficient second amount of at least one chlorite salt dispersion; where, when the composition is contacted with an aqueous liquid, the sufficient first amount of the first active agent dispersion and the sufficient second amount of the at least one chlorite salt dispersion results in a generation of chlorine dioxide radicals.

An embodiment includes a wound dressing comprising: a shape memory polymer (SMP) foam, including open cells, having first and second states; and a hydrogel (HG) included within the cells; wherein (a) in a first position a composite, including the SMP foam and the HG, is configured to be located proximate a hemorrhagic tissue with the SMP foam in the first state; (b) in a second position the composite is configured to be expanded to the second state against the hemorrhagic tissue when the SMP foam is plasticized at 37 C. depressing a glass transition temperature (T.sub.g) of the SMP foam to below 25 C. Other embodiments are described herein.

The invention relates to a hemostatic composition comprising a mixture of cellulose-based short and long fibers, preparation and use thereof.

The present invention relates to improved hemostatic compositions comprising cellulose-based fibers supplemented with compounds, preparation and use thereof.

The present application relates to bioactive implants, methods of making bioactive implants, and methods of using bioactive implants to treat or repair a bone defect or a cartilage defect. In an aspect, the present application relates to compositions comprising bone microparticles in a solution, wherein the compositions harden upon desiccation into bioactive implants. In an aspect, the present application relates to compositions comprising cartilage microparticles in a solution, wherein the compositions harden upon desiccation into bioactive implants. In an aspect, disclosed herein are methods of making and using the disclosed compositions comprising bone microparticles and the disclosed composition comprising cartilage microparticles. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

A bandage assembly for treating a patient's wound can consist of outer, inner, and adhesive layers. The outer layer may be constructed of a first material and have a window portion that is a semitransparent second material. The inner layer can be suspended across the window portion and be coated with at least one medication material. The adhesive layer may be disposed between and contact the outer layer as well as skin of a patient to apply continuous pressure on the inner layer.

An antiseptic composition suitable for use on skin and wounds comprising a source of an antimicrobial agent and an agent which disrupts biofilms. More, particularly the invention relates to a composition capable of providing effective antimicrobial activity while at the same time avoiding wound and skin irritation and retardation of wound healing.

Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.

Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%), or more specifically between about 0.015% to about 5%, sodium iodine or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.